BIVI - מכפיל EV/EBITDA BioVie

BioVie Inc. (BIVI) focuses on developing small molecules for the treatment of neurodegeneration and severe liver pathologies. However, the business faces significant challenges, including a high burn rate and dependence on the FDA's verdict regarding the drug NE3107. The market value dynamics of the asset in terms of EV/EBITDA currently stand at 0.00. Stable management aims to successfully complete the trials, although shareholder confidence fluctuates sharply in line with research results.

Stable laboratory utilization and the continuity of chemical analysis at BioVie Inc. (BIVI) establish a foundation for assessing operational expenditure efficiency. An analysis of business valuation via EV/EBITDA allows for the correlation of the company's total enterprise value with its earnings before interest, taxes, depreciation, and amortization, determining whether quotes are overheated or the model has reached maturity, which is critical for understanding the issuer's capital stability.